Figure 6.
Figure 6. Inflammatory phenotype of STI-571–treated APCs. Bone marrow–derived DCs (A) or PEMs (B) were treated with either LPS (5 μg/mL) or LPS plus 10μM STI-571 for 24 hours. Then total RNA was isolated and RNA protection assay (RPA) was carried out using chemokine and cytokine multiprobe templates according to the manufacturer's protocol (BD Pharmingen). RPA was repeated 3 times with similar results.

Inflammatory phenotype of STI-571–treated APCs. Bone marrow–derived DCs (A) or PEMs (B) were treated with either LPS (5 μg/mL) or LPS plus 10μM STI-571 for 24 hours. Then total RNA was isolated and RNA protection assay (RPA) was carried out using chemokine and cytokine multiprobe templates according to the manufacturer's protocol (BD Pharmingen). RPA was repeated 3 times with similar results.

Close Modal

or Create an Account

Close Modal
Close Modal